Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EPS (Basic) (2017 - 2025)

Historic EPS (Basic) for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$0.97.

  • Dianthus Therapeutics' EPS (Basic) fell 3108.11% to -$0.97 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.49, marking a year-over-year decrease of 14874.3%. This contributed to the annual value of -$2.54 for FY2024, which is 6998.28% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported EPS (Basic) of -$0.97 as of Q3 2025, which was down 3108.11% from -$0.88 recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' EPS (Basic) registered a high of $8.95 during Q4 2023, and its lowest value of -$12.73 during Q2 2023.
  • Moreover, its 4-year median value for EPS (Basic) was -$0.88 (2025), whereas its average is -$3.19.
  • As far as peak fluctuations go, Dianthus Therapeutics' EPS (Basic) surged by 17735.52% in 2023, and later plummeted by 10936.61% in 2024.
  • Dianthus Therapeutics' EPS (Basic) (Quarter) stood at -$11.57 in 2022, then skyrocketed by 177.36% to $8.95 in 2023, then crashed by 109.37% to -$0.84 in 2024, then dropped by 15.71% to -$0.97 in 2025.
  • Its EPS (Basic) stands at -$0.97 for Q3 2025, versus -$0.88 for Q2 2025 and -$0.82 for Q1 2025.